



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

BRIGATINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BRIGATINIB	ALUNBRIG	44226		GPI-10 (2153051000)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
 - The patient is 18 years of age or older
 - The patient is positive for anaplastic lymphoma kinase (ALK) fusion oncogene as detected by an FDA-approved test

If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**

- **Alunbrig 30mg: #120 per 30 days.**
- **Alunbrig 90mg: #30 per 30 days.**
- **Alunbrig 180mg: #30 per 30 days.**
- **Alunbrig 90mg-180mg initiation pack: #30 per 30 days.**

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BRIGATINIB (Alunbrig)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. You are positive for anaplastic lymphoma kinase (ALK) fusion oncogene (a type of gene mutation that causes a change in your DNA) as detected by a Food and Drug Administration (FDA)-approved test

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Alunbrig.

REFERENCES

- Alunbrig [Prescribing Information]. Cambridge, MA: Ariad Pharmaceuticals; May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/10/21

Created: 07/17

Client Approval: 03/21

P&T Approval: 07/20

Copyright © 2021 MediImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MediImpact. MediImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.